Insider selling
Traded Nov 16 · filed 2 days laterNot reported under a pre-arranged trading plan
A Regeneron Pharmaceuticals director sold $960K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 4, 2026 · Filed Nov 6, 2026
Regeneron Pharmaceuticals's SVP Controller sold $33K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$33,096
Shares × reported transaction price
5 days after results of Oct 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $930.67 on Nov 4, 2026, within 5% of its 52-week high, after a 16% rise over the previous 30 trading days
52-week range $600.66 (Jun 1, 2026) to $973.36 (Nov 3, 2026), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $801.82 on Sep 23, 2026. Describes the past only, not a forecast
RSI 70, 26% above its 200-day average, 16% above its 50-day average, 4% below the 52-week high, 20-day volatility 53% a year, against the S&P 500: +28 points over 1 month, +21 points over 3 months, +25 points over 6 months
From the adjusted closes up to Nov 4, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Sep 23, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
2 such cases were open. Hopkinson v. Regeneron Pharmaceuticals, Inc., docket 7:26-cv-08311, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.5% | −1.7% | +5.2% |
Past results only. Not a forecast.
Insider selling
Traded Nov 16 · filed 2 days laterNot reported under a pre-arranged trading plan
A Regeneron Pharmaceuticals director sold $960K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 17 · filed 1 day laterNot reported under a pre-arranged trading plan
A Regeneron Pharmaceuticals director sold $168K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 17 · filed 1 day laterNot reported under a pre-arranged trading plan
A Regeneron Pharmaceuticals director sold $344K of Regeneron Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.